242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach

MLA

L. Palmero, et al. “242P Investigating the Risk of Drug-Induced Interstitial Lung Disease in Patients with Metastatic Breast Cancer Treated with AntiHER2 Regimens through a Network Meta-Analysis Approach.” Annals of Oncology, vol. 33, Sept. 2022, p. S648. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.281.

APA

L. Palmero, M.A. Siciliano, P. Di Nardo, D. Basile, L. Cucciniello, B. Pastò, C. Lisanti, A. Membrino, C. Noto, S. Spazzapan, L. Gerratana, & F. Puglisi. (2022). 242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach. Annals of Oncology, 33, S648. https://doi.org/10.1016/j.annonc.2022.07.281

Chicago

L. Palmero, M.A. Siciliano, P. Di Nardo, D. Basile, L. Cucciniello, B. Pastò, C. Lisanti, et al. 2022. “242P Investigating the Risk of Drug-Induced Interstitial Lung Disease in Patients with Metastatic Breast Cancer Treated with AntiHER2 Regimens through a Network Meta-Analysis Approach.” Annals of Oncology 33 (September): S648. doi:10.1016/j.annonc.2022.07.281.